<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnostic evaluation of the hemodynamically stable adult with a pleural effusion</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnostic evaluation of the hemodynamically stable adult with a pleural effusion</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnostic evaluation of the hemodynamically stable adult with a pleural effusion</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">YC Gary Lee, MBChB, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fabien Maldonado, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pleural effusions can develop as a result of over 50 different pleuropulmonary or systemic disorders of both benign and malignant etiologies. Consequently, the evaluation of patients with a pleural effusion is challenging since the differential diagnosis is broad. Making a prompt diagnosis is important so that serious conditions such as malignancy and tuberculosis are not missed.</p><p>This topic will provide an overview the diagnostic approach to a pleural effusion including the indications for thoracentesis. It will not include evaluation of the unstable patient with traumatic hemothorax. Pleural effusion imaging, pleural fluid analysis, and evaluation of traumatic hemothorax are discussed separately. (See  <a class="medical medical_review" href="/d/html/6686.html" rel="external">"Ultrasound-guided thoracentesis"</a> and  <a class="medical medical_review" href="/d/html/6688.html" rel="external">"Imaging of pleural effusions in adults"</a> and  <a class="medical medical_review" href="/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion"</a> and  <a class="medical medical_review" href="/d/html/353.html" rel="external">"Initial evaluation and management of blunt thoracic trauma in adults", section on 'Hemothorax'</a>.)</p><p class="headingAnchor" id="H14505589"><span class="h1">INITIAL APPROACH</span></p><p class="headingAnchor" id="H2"><span class="h2">History and examination</span><span class="headingEndMark"> — </span>The history and examination are critical for narrowing the differential and deciding what pleural fluid biomarkers should be obtained for initial pleural fluid analysis. Although pleural effusion has a wide array of etiologies, large series have shown that cancer, heart failure, and parapneumonic infections account for most cases [<a href="#rid1">1</a>]. Thus, we pay particular attention to comorbid conditions (particularly congestive heart failure) but also underlying lung disease and risk factors that might predispose a patient to pneumonia, tuberculosis (TB), and lung cancer.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comorbid conditions</strong> – We inquire about any heart, liver, or renal disease that may predispose patients to a pleural effusion due to fluid overload. We also inquire about lung conditions that may predispose a patient to parapneumonic effusion or malignant pleural effusion (eg, chronic bronchitis, bronchiectasis, immune deficiency).</p><p></p><p class="bulletIndent1">The patient may have a known disorder that may raise the suspicion for other less common causes of a pleural effusion including systemic lupus erythematosus (pleuritic exudate), hypothyroidism (transudative pleural effusion), amyloidosis (exudative pleural effusion), pancreatitis (amylase-rich pleural effusion), lymphangioleiomyomatosis (chylous effusion), rheumatoid arthritis (cholesterol effusion), and immunoglobulin G4 (pleuritic exudate). (See  <a class="medical medical_review" href="/d/html/4681.html" rel="external">"Pulmonary manifestations of systemic lupus erythematosus in adults"</a> and  <a class="medical medical_review" href="/d/html/5589.html" rel="external">"Overview of amyloidosis"</a>.)</p><p></p><p class="bulletIndent1">When the pleural effusion is large or underling lung disease is severe, it may be difficult to distinguish symptoms due to an underlying pulmonary cause from those due to the pleural effusion. For example, dyspnea, cough, and chest pain can occur with a pleural effusion and underlying pneumonia. However, the contribution of pleural disease may be more apparent after therapeutic thoracentesis. (See  <a class="medical medical_review" href="/d/html/6686.html" rel="external">"Ultrasound-guided thoracentesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Signs and symptoms of pneumonia or tuberculosis</strong> – We ask about symptoms of a respiratory tract infection such as cough, sputum production, hemoptysis, fever, history of aspiration, immunosuppression (eg, human immunodeficiency virus [HIV]).</p><p></p><p class="bulletIndent1">We inquire about exposure to TB, travel to countries where TB is endemic, or past history of TB.</p><p></p><p class="bulletIndent1">A recent history of pneumonia (eg, in the prior 6 months) should raise the suspicion for nonexpandable lung due to an undiagnosed parapneumonic pleural effusion that is undergoing organization. Slowly resolving pneumonia should also raise the suspicion for a malignant pleural effusion. (See  <a class="medical medical_review" href="/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults"</a>.)</p><p></p><p class="bulletIndent1">A recent history of vomiting in a patient who is sick with suspected aspiration pneumonia may raise the suspicion for a ruptured esophagus due to Boerhaave syndrome (amylase-rich pleural effusion).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms of or risk factors for malignancy</strong> – The patient may have a known history of active cancer or be receiving medications that can cause a pleural effusion. We ask about hemoptysis, weight loss, fatigue, night sweats, smoking, change in bowel habit, breast lumps, recent mammography, or skin abnormalities.</p><p></p><p>Other pertinent questions are focused on less common etiologies and may or may not be apparent on initial presentation. These include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug and occupational history</strong> – A careful drug history may reveal that the patient is taking <a class="drug drug_general" data-topicid="9704" href="/d/drug information/9704.html" rel="external">nitrofurantoin</a>, <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>, ovarian stimulation therapy, or a drug that can produce a lupus-like syndrome (eg, <a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">hydralazine</a>) [<a href="#rid2">2,3</a>]. (See  <a class="medical medical_review" href="/d/html/4677.html" rel="external">"Drug-induced lupus"</a>.)</p><p></p><p class="bulletIndent1">Patients may also be taking immunotherapy and have immunotherapy-related pleural effusion [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p></p><p class="bulletIndent1">We inquire about potential asbestos exposure, which might suggest mesothelioma or a benign asbestos pleural effusion, even if exposure may have occurred many years earlier [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recent procedures</strong> – Recent procedures should prompt the clinician to suspect procedure-related pleural effusion such as central line insertion (catheter misplacement), bladder washes (glycinothorax), urinary or biliary intervention (urino- and bilo-thorax, respectively), cerebrospinal fluid (CSF) shunt placement (CSF shunt-related pleural effusion), or thoracoabdominal surgery (fluid overload, hemorrhage, cardiac surgery-related pleural effusion).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential extra-pleural sources</strong> – Pleural fluid may originate from extrapleural sources, most commonly from transdiaphragmatic movement. A detailed history and examination for ascites (hepatic hydrothorax) and urinary tract obstruction (urinothorax) are important. Patients receiving peritoneal dialysis (PD) are at risk of developing a PD-related pleural effusion  (<a class="graphic graphic_table graphicRef122224" href="/d/graphic/122224.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/119910.html" rel="external">"Pleural effusion of extra-vascular origin (PEEVO)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Miscellaneous</strong> – Rare etiologies are often not initially apparent but may be considered after the initial pleural fluid analysis suggests a possible etiology (eg, milky fluid may suggest chylothorax  (<a class="graphic graphic_table graphicRef61456" href="/d/graphic/61456.html" rel="external">table 2</a>)).</p><p></p><p class="bulletIndent1">The patient may have a recent history of falls, which may prompt suspicion for hemothorax or a history of aggressive fluid resuscitation for shock or sepsis, which may suggest fluid overload.</p><p></p><p class="headingAnchor" id="H3599050973"><span class="h2">Advanced thoracic imaging</span><span class="headingEndMark"> — </span>In most patients, we perform advanced thoracic imaging, particularly bedside thoracic ultrasound, which is now widely available. Point-of-care thoracic ultrasonography can rapidly provide information on effusion size and the presence of loculations or pleural masses. Further information on thoracic ultrasonography is provided separately. (See  <a class="medical medical_review" href="/d/html/14888.html" rel="external">"Bedside pleural ultrasonography: Equipment, technique, and the identification of pleural effusion and pneumothorax"</a> and  <a class="medical medical_review" href="/d/html/14867.html" rel="external">"Indications for bedside ultrasonography in the critically ill adult patient"</a>.)</p><p>While chest computed tomography (CT) is not necessary in every case of pleural effusion, it is useful in the following scenarios [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>When the etiology is not obvious</p><p class="bulletIndent1"><span class="glyph">●</span>When the pleural effusion appears complex and loculated</p><p class="bulletIndent1"><span class="glyph">●</span>When malignancy or other diseases more apparent on CT are suspected (eg, lymphangioleiomyomatosis [LAM])</p><p></p><p>When CT is indicated, we typically obtain pleural-phase contrast enhancement scans. Irregular or thickened pleura with contrast enhancement suggests pleural inflammation or malignancy and identifies optimal sites for CT-guided needle aspiration or cutting needle biopsy. (See  <a class="medical medical_review" href="/d/html/4399.html" rel="external">"Imaging of pleural plaques, thickening, and tumors"</a>.)</p><p>Chest CT may also reveal underlying abnormalities that are directly related to the etiology of the pleural effusion and help narrow the differential. These include conditions such as a lung mass, hilar or mediastinal lymphadenopathy, pneumonic consolidation, cystic lung diseases, or old TB calcification patterns.</p><p>CT is also valuable in detecting extra-pulmonary clues to the causes of pleural effusions, such as fractured ribs, pericardial effusions (often obscured by pleural effusion on chest radiographs), esophageal abnormalities, ascites, and pathologies in upper abdominal organs (eg, pancreas).</p><p class="headingAnchor" id="H1596976703"><span class="h1">THORACENTESIS INDICATIONS AND CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>Thoracentesis is a percutaneous procedure where pleural fluid is removed either through a needle (typically for small volumes [eg, &lt;30 mL]), needle over catheter system, or a small-bore catheter. The location for this procedure is most often bedside in an inpatient setting, but the same technique can be used for those in an emergency room, operating room, or outpatient setting. Although referral of patients to interventional radiology services for image-guided thoracentesis may be convenient, referral is more costly and no safer than performing ultrasound-guided thoracentesis in the clinic or at the bedside by appropriately trained clinicians [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H4128796932"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Thoracentesis may be diagnostic and/or therapeutic:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic (new effusion of unclear etiology)</strong> – Most patients who have a newly detected pleural effusion of unclear etiology should undergo diagnostic thoracentesis to determine the nature of the pleural effusion (ie, transudate, exudate) and to identify potential causes.</p><p></p><p class="bulletIndent1">The exceptions are when there is only a small amount of pleural fluid with a secure clinical diagnosis (eg, pneumonia) or when there is clinically obvious congestive heart failure (CHF) with typical features (eg, bilateral pleural effusions and pulmonary edema) [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1">In a patient with suspected CHF, atypical features that should prompt consideration of diagnostic thoracentesis include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Features that suggest an alternate etiology for the effusion (eg, unilateral or bilateral effusions of significantly disparate sizes, especially if the effusion on the left is larger than on the right)</p><p class="bulletIndent2"><span class="glyph">•</span>Symptoms of pleurisy or fever</p><p class="bulletIndent2"><span class="glyph">•</span>Features suggestive of infection or cancer</p><p class="bulletIndent2"><span class="glyph">•</span>An echocardiogram that is not consistent with CHF</p><p class="bulletIndent2"><span class="glyph">•</span>A disproportionately wide alveolar-arterial oxygen gradient</p><p class="bulletIndent2"><span class="glyph">•</span>The lack of resolution with effective CHF therapy</p><p></p><p class="bulletIndent1">For patients with pleural effusions who do not undergo thoracentesis, we follow them clinically and the effusion is followed radiologically. We have a low threshold to perform thoracentesis if the effusion does not respond as anticipated. This approach is based upon the rationale that up to one-third of patients with a clinically apparent cause of a pleural effusion, such as heart failure, have more than one etiology that can be readily distinguished by pleural fluid analysis (eg, heart failure plus either pneumonia or pulmonary embolism) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapeutic (symptom relief)</strong> – Therapeutic thoracentesis is commonly performed for symptom relief (eg, dyspnea) or if the fluid has imaging characteristics of a complicated pleural effusion (eg, loculations suggesting a parapneumonic pleural effusion). (See  <a class="medical medical_review" href="/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults"</a>.)</p><p></p><p class="bulletIndent1">Choosing between a one-time therapeutic thoracentesis or insertion of a small-bore chest tube or catheter for one or more days is dependent upon patient-related factors including effusion size and character (loculated or free flowing), the need for complete drainage, institutional factors, operator preference, and availability of expertise.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of complications</strong> – Thoracentesis is also indicated for patients with pleural conditions that risk pleural thickening and restrictive functional impairment, should they not be drained. Examples include pleural effusions due to post-primary or reactivation tuberculosis and hemothorax.</p><p></p><p class="headingAnchor" id="H221339618"><span class="h2">Contraindications</span><span class="headingEndMark"> — </span>Contraindications to thoracentesis include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insufficient pleural fluid</strong> – Thoracentesis is not justified for small free-flowing pleural effusions because of the low diagnostic yield and high risk of pneumothorax. The "safe window" for thoracentesis on ultrasonography has been estimated as a point where maximum pleural fluid depth is &gt;1 cm adjacent to the parietal pleura [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/6686.html" rel="external">"Ultrasound-guided thoracentesis", section on 'Locating fluid'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin infection or wound at the needle insertion site</strong> – Active skin infection at the point of needle insertion is a contraindication due to the risk of introducing pleural space infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe bleeding diathesis</strong> – It is not clear whether a bleeding diathesis should be corrected prior to the procedure or whether any specific laboratory result represents excessive bleeding risk that serves as a contraindication to thoracentesis [<a href="#rid11">11-13</a>].</p><p></p><p class="bulletIndent1">While older retrospective series demonstrated increased risk of bleeding in patients with a coagulopathy (eg, International Normalized Ratio [INR] &gt;2), thrombocytopenia (platelet count &lt;50,000 platelets/mm<sup>3</sup>), or a serum creatinine concentration &gt;6 mg/dL [<a href="#rid14">14</a>], case series performed in the era of ultrasound guidance do not demonstrate an increased risk of bleeding in these settings in most patients [<a href="#rid11">11,15-18</a>].</p><p></p><p class="bulletIndent1">In the absence of data, decisions to reverse the coagulopathy or correct the thrombocytopenia should be individualized and based on perceived benefit-to-risk ratios and urgency of thoracentesis. The benefits should be weighed against the probability of bleeding into the pleural space as well as the ability of a patient to tolerate a hemothorax and a procedure to drain intrapleural blood, should that be needed. For instance, for patients with an indication that represents an urgent need for pleural fluid analysis, such as possible acute hemothorax, we proceed quickly to thoracentesis without correcting a bleeding diathesis. In contrast, if pleural fluid analysis is not immediately needed, such as for a patient with suspected pleural malignancy, we reverse a coagulopathy when the INR is &gt;1.5 or administer platelets when the platelet count is &lt;50,000 platelets/mm<sup>3</sup>.</p><p></p><p>Mechanical ventilation is not considered a contraindication to thoracentesis. While patients receiving mechanical ventilation who undergo ultrasound-guided thoracentesis may be at increased risk of pneumothorax, particularly tension pneumothorax [<a href="#rid17">17,19-21</a>], the rate is low. The use of positive end-expiratory pressure does not increase pneumothorax risk [<a href="#rid19">19</a>] (see  <a class="medical medical_review" href="/d/html/6686.html" rel="external">"Ultrasound-guided thoracentesis", section on 'Complications'</a>). However, the consequences of developing a post-procedural pneumothorax will be more significant in a patient already requiring ventilatory support. This needs to be factored into the benefit-to-risk calculation.</p><p>The technique of performing ultrasound-guided thoracentesis is provided separately. (See  <a class="medical medical_review" href="/d/html/6686.html" rel="external">"Ultrasound-guided thoracentesis"</a>.)</p><p class="headingAnchor" id="H1651555252"><span class="h1">INITIAL PLEURAL FLUID ANALYSIS</span><span class="headingEndMark"> — </span>For patients who undergo diagnostic thoracentesis, we obtain general biomarkers (eg, cell counts and cell differential, total protein, lactate dehydrogenase, glucose, cholesterol) and condition-specific pleural fluid biomarkers (eg, pleural fluid culture and Gram stain when infection is suspected, cytology if malignancy is suspected, lipid analysis if chylothorax is suspected). Initial general and specific biomarkers that should be obtained and their interpretation are discussed separately. (See  <a class="medical medical_review" href="/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion"</a>.)</p><p class="headingAnchor" id="H3946866149"><span class="h1">MAKING A PRELIMINARY DIAGNOSIS</span><span class="headingEndMark"> — </span>In most patients, a diagnosis can be achieved using an approach that combines clinical evaluation and imaging with comprehensive pleural fluid analysis. Occasionally, a second thoracentesis may be needed for pleural fluid analysis especially when the first analysis increases the suspicion for a select diagnosis and additional condition-specific diagnostic markers need to be obtained  (<a class="graphic graphic_table graphicRef74757" href="/d/graphic/74757.html" rel="external">table 3</a>).</p><p>The diagnosis is typically easily made in patients who clearly have a transudative  (<a class="graphic graphic_table graphicRef73530" href="/d/graphic/73530.html" rel="external">table 4</a>) or an exudative  (<a class="graphic graphic_table graphicRef54055" href="/d/graphic/54055.html" rel="external">table 5</a>) pleural effusion with positive condition-specific biomarkers in the right clinical setting. Common diagnoses that are made using this approach are listed in the tables  (<a class="graphic graphic_table graphicRef50027" href="/d/graphic/50027.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef139766" href="/d/graphic/139766.html" rel="external">table 7</a>).</p><p>However, in some patients, the diagnosis is not clear and further evaluation is needed. This evaluation is provided below. (See <a class="local">'Additional evaluation for unclear etiology'</a> below and <a class="local">'Etiology remains undetermined'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h1">ADDITIONAL EVALUATION FOR UNCLEAR ETIOLOGY</span><span class="headingEndMark"> — </span>The cause of a pleural effusion is not evident in an estimated one-quarter of patients despite clinical evaluation and pleural fluid analysis [<a href="#rid22">22</a>]. The numbers vary among series significantly because it depends on the setting and patient population studied. These patients are often deemed as having an "undiagnosed pleural effusion," although no universally accepted definition exists for these patients. In this group of patients, the etiologic diagnosis can be challenging. As such, subspecialty consultation with a pulmonologist is reasonable to assess the need for all or any of the following options:</p><p class="bulletIndent1"><span class="glyph">●</span>We typically rereview the history and examination and reanalyze the pleural fluid. (See <a class="local">'Retake the history and examination'</a> below and <a class="local">'Reanalyze pleural fluid'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If indicated, we perform additional imaging targeted at confirming suspected etiologies or excluding serious etiologies (eg, positron emission tomography [PET] or CT pulmonary angiography). (See <a class="local">'Consider additional imaging'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the etiology still remains undetermined at this point, we typically perform a pleural biopsy with the goal of confirming or excluding serious pathologies that can be diagnosed on pleural biopsy, such as cancer or tuberculosis (TB). (See <a class="local">'Pleural biopsy'</a> below.)</p><p></p><p class="headingAnchor" id="H3599889646"><span class="h2">Retake the history and examination</span><span class="headingEndMark"> — </span>For patients with pleural effusion of undetermined etiology, we rereview the history and examination to find etiologic clues that were potentially overlooked. We also consider the possibility of uncommon or rare etiologies (eg, yellow nail syndrome, lymphatic diseases, cholesterol effusion, and chylothorax). These details are provided above. (See <a class="local">'History and examination'</a> above.)</p><p class="headingAnchor" id="H1547798624"><span class="h2">Reanalyze pleural fluid</span><span class="headingEndMark"> — </span>This may involve recalculation of the criteria used to distinguish transudative  (<a class="graphic graphic_table graphicRef73530" href="/d/graphic/73530.html" rel="external">table 4</a>) and exudative  (<a class="graphic graphic_table graphicRef54055" href="/d/graphic/54055.html" rel="external">table 5</a>) effusions. This recalculation is particularly important in patients with results that are borderline or discordant (with clinical suspicion or each other). Reanalysis may also involve adding condition-specific biomarkers if needed and/or reanalyzing a fresh sample of pleural fluid.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distinguishing transudative and exudative effusions</strong> – Interpretation of pleural fluid biochemistry must take into consideration the clinical context. This is especially the case when pleural fluid analysis is borderline for transudate/exudate parameters and/or discordant with the clinical suspicion (eg, exudate in a patient with classic features of heart failure). In these circumstances, we use additional pleural fluid tests (eg, using a different formula or biomarker) and imaging analyses in conjunction with clinical judgment to distinguish transudative from exudative causes of pleural effusions.</p><p></p><p class="bulletIndent1">For example, in patients with cardiac failure receiving diuretic therapy, the transudative pleural fluid may have an elevated protein level and be mistakenly classified as an exudate. Calculating a serum-to-pleural fluid gradient for albumin or protein may reclassify the effusion as a transudate. (See  <a class="medical medical_review" href="/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion", section on 'Albumin and protein gradients'</a>.)</p><p></p><p class="bulletIndent1">In patients with borderline or discrepant results, we also consider the possibility that the pleural effusion has more than one cause [<a href="#rid23">23</a>]. One study of 130 patients with a unilateral pleural effusion found that 30 percent had more than one cause for the effusion [<a href="#rid9">9</a>]. If those causes contain concomitant transudative and exudative etiologies (eg, malignancy in a patient with heart failure), the resultant effusion can either be a transudate  (<a class="graphic graphic_table graphicRef73530" href="/d/graphic/73530.html" rel="external">table 4</a>) or exudate. In such cases, it may not be possible to clearly distinguish a transudate from an exudate and additional biomarkers and/or pleural biopsy may be needed for diagnosis.</p><p></p><p class="bulletIndent1">It is also important to note that in some cases of malignant pleural effusion, a proportion present with transudative effusion (eg, up to 10 percent), perhaps because there is another etiology for the effusion or because pleural involvement is early or minimal.</p><p></p><p class="bulletIndent1">Further details regarding distinguishing transudative from exudative effusions are provided separately. (See  <a class="medical medical_review" href="/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion", section on 'Classification as exudative or transudative'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Add condition-specific biomarkers, when indicated</strong> – We consider obtaining additional specific biomarkers when the suspicion for a diagnosis becomes more apparent after the initial thoracentesis. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When heart failure is suspected but the pleural fluid is borderline exudative, some experts measure the total protein or albumin gradient. While obtaining pleural fluid N-terminal pro-brain natriuretic peptide (NT-proBNP) is sometimes performed in this population, measuring pleural NT-proBNP has no added value over serum values. (See  <a class="medical medical_review" href="/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion", section on 'Suspected heart failure-related pleural effusion'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similarly, if a cholesterol or chylous effusion is suspected, we obtain pleural fluid triglycerides and cholesterol levels and consider definitive tests such as chylomicrons (chylous effusion) and microscopic examination for cholesterol crystals (cholesterol effusion). (See  <a class="medical medical_review" href="/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion", section on 'Suspected chylous or cholesterol effusion'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with a lymphocytic effusion, further investigation should be considered for TB (eg, adenosine deaminase), lymphoma (cytometry, flow cytometry), chylothorax (triglycerides), and pseudochylothorax (cholesterol) [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion", section on 'Interpreting individual biomarkers'</a>.)</p><p></p><p class="bulletIndent1">Specific biomarkers for select suspected conditions are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion", section on 'Condition-specific biomarkers'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repeat pleural fluid analysis</strong> – In some patients, repeating pleural fluid analysis is helpful if additional tests are needed (especially involving tests that cannot be performed on stored fluid). As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Repeating pleural fluid cytology may increase the chances of obtaining a diagnosis of a malignant pleural effusion modestly, although the yield may differ among cancer types. For example, pleural fluid analysis may be more useful in adenocarcinoma than in sarcoma or renal cell carcinoma. (See  <a class="medical medical_review" href="/d/html/89115.html" rel="external">"Procedures for tissue biopsy in patients with suspected non-small cell lung cancer", section on 'Suspected pleural metastases'</a> and  <a class="medical medical_review" href="/d/html/88822.html" rel="external">"Selection of modality for diagnosis and staging of patients with suspected non-small cell lung cancer", section on 'Pleural (T2, T3, M1a)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fresh sample may also be needed for repeat microbiologic culture and pH in patients with suspected parapneumonic effusion or flow cytometry in patients with suspected lymphoma. (See  <a class="medical medical_review" href="/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults", section on 'Thoracentesis and pleural fluid analysis'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Consider additional imaging</span><span class="headingEndMark"> — </span>In patients in whom a pleural effusion is suspected to be due to pulmonary embolism (PE), we perform imaging targeted at diagnosing PE (eg, CT pulmonary angiography). Two studies of 60 [<a href="#rid25">25</a>] and 230 [<a href="#rid26">26</a>] patients with PE showed that 47 to 48 percent had a pleural effusion, the majority of which were small and did not require drainage. Large effusions should alert clinicians to alternative or additional causes of fluid formation other than PE.</p><p>PET/CT may be indicated when malignancy is suspected, although a negative PET/CT does not exclude malignancy nor does a positive one confirm it [<a href="#rid27">27</a>]. Suspicious findings may help guide biopsy. PET/CT may also highlight extrapleural abnormalities that may be associated with the cause of the effusion (eg, bony metastases).</p><p>Ultrasonography can be helpful in the etiologic evaluation of pleural effusion and help guide biopsy under direct image-guidance. Pleural nodularity and thickening of the diaphragm (&gt;7 mm) and pleura (&gt;1 cm) are strong predictors of malignant pleural diseases with a positive predictive value of 100 percent if all are present [<a href="#rid28">28</a>]. (See <a class="local">'Pleural biopsy'</a> below.)</p><p>Magnetic resonance imaging may be useful when examining chest wall invasion by local tumors [<a href="#rid29">29</a>].</p><p>Imaging of the pleura is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6688.html" rel="external">"Imaging of pleural effusions in adults"</a> and  <a class="medical medical_review" href="/d/html/4399.html" rel="external">"Imaging of pleural plaques, thickening, and tumors"</a> and  <a class="medical medical_review" href="/d/html/14888.html" rel="external">"Bedside pleural ultrasonography: Equipment, technique, and the identification of pleural effusion and pneumothorax", section on 'Identification of malignant pleural disease'</a>.)</p><p class="headingAnchor" id="H3143843043"><span class="h1">ETIOLOGY REMAINS UNDETERMINED</span><span class="headingEndMark"> — </span>If the etiology still remains undetermined following additional evaluation, we typically perform a pleural biopsy. The major goal of a pleural biopsy is to confirm or exclude serious conditions that can be diagnosed pathologically, such as cancer (including mesothelioma), tuberculosis (TB), or other infection.</p><p class="headingAnchor" id="H9"><span class="h2">Pleural biopsy</span></p><p class="headingAnchor" id="H4203107570"><span class="h3">Choosing biopsy mode</span><span class="headingEndMark"> — </span>A number of techniques for pleural biopsy are available. These include CT-guided (or ultrasound-guided) pleural biopsy, thoracoscopic pleural biopsy, closed pleural biopsy, and open pleural biopsy. Choosing among the available options is dependent upon factors including the suspected etiology, local expertise, and type of pleural involvement (eg, focal or diffuse, mass or ill-defined thickening). Open pleural biopsy by thoracotomy and closed pleural biopsy have been largely replaced by image-guided or thoracoscopic techniques [<a href="#rid30">30</a>]. In general, definitive diagnosis is more likely with thoracoscopic biopsy and is widely used. However, in communities where TB is endemic and tuberculous involvement is likely to be diffuse, closed biopsy is still commonly used. Data to support one of the other varies depending on the patient population being studied and the skill of the operator.</p><p class="headingAnchor" id="H3570366918"><span class="h4">Diffuse pleural involvement: Closed pleural biopsy</span><span class="headingEndMark"> — </span>For patients with conditions where the pleura is likely to be diffusely involved (eg, tuberculous or rheumatoid pleuritis), a closed pleural biopsy is useful. For patients in whom the pleural disease process is expected to be patchy, such as suspected malignant pleural effusions, we do not use a closed pleural biopsy since the yield is likely to be low. In general, multiple biopsies are performed to increase the diagnostic yield of the study (eg, four or fewer biopsies). If this expertise is not available and the disease thought to be diffuse, then image-guided or thoracoscopics pleural biopsy can be used to obtain pleural tissue.</p><p>Limited data and our experience support the value of closed pleural biopsy in patients suspected to have diffusely involved pleural disease. In a randomized trial of 89 patients with suspected TB pleuritis, closed pleural biopsy using an Abrams needle (of at least four tissue pieces) and ultrasound guidance yielded pleural tissue in 91 percent of cases and successfully diagnosed TB pleuritis in 82 percent of patients, which was superior to closed pleural biopsy using Tru-Cut needles (78 and 65 percent, respectively) [<a href="#rid31">31</a>]. In another trial the sensitivity of a closed biopsy using an Abrams needle was lower at 47 percent [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H3672973631"><span class="h4">Pleural mass or thickening: Image-guided pleural biopsy</span><span class="headingEndMark"> — </span>In patients whose pleural effusion is associated with pleural-based abnormalities (eg, pleural-based mass or thickening), we typically prefer image-guided biopsy since it has a higher yield than closed (blinded) percutaneous biopsy. The choice between ultrasound- and CT-guidance depends on local expertise and availability as well as patient factors.</p><p>Limited data support image-guided biopsy in patients with undiagnosed pleural effusion and pleural-based abnormality:</p><p class="bulletIndent1"><span class="glyph">●</span>Ultrasonography – In a randomized study of 150 patients with undiagnosed pleural effusion, ultrasound-guided biopsy had a sensitivity of 67 percent compared with 82 percent using CT-guided Abrams needle biopsy [<a href="#rid33">33</a>]. In contrast, in 196 patents with suspected TB pleuritis, ultrasound-guided pleural biopsy had similar diagnostic sensitivity as thoracoscopy (82 versus 90 percent), likely due to the diffuse nature of the disease [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CT – A randomized trial of 124 patients with suspected malignant pleural diseases showed that CT-guided biopsy had a yield of 88 percent compared with 94 percent with thoracoscopy [<a href="#rid35">35</a>]. In another randomized trial of 50 patients with a pleural effusion and pleural thickening suspected to be malignant, the sensitivity of CT-guided cutting needle biopsy was greater than that of a closed Abrams biopsy (87 percent versus 47 percent) [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1">The efficacy of CT-guided biopsy in the setting of suspected cancer is discussed separately. (See  <a class="medical medical_review" href="/d/html/89115.html" rel="external">"Procedures for tissue biopsy in patients with suspected non-small cell lung cancer", section on 'Suspected pleural metastases'</a>.)</p><p></p><p class="headingAnchor" id="H578958426"><span class="h4">Patchy pleural involvement: Thoracoscopic pleural biopsy</span><span class="headingEndMark"> — </span>In patients whose pleural effusion is not associated with an obvious mass on CT or when percutaneous biopsy is negative or patchy disease is suspected, we typically prefer thoracoscopic pleural biopsy, especially when malignancy is suspected. When compared with closed or image-guided biopsy, thoracoscopy has the advantage of visual inspection and targeted biopsy of visually abnormal regions of the pleura. (See  <a class="medical medical_review" href="/d/html/4388.html" rel="external">"Medical thoracoscopy (pleuroscopy): Equipment, procedure, and complications"</a> and  <a class="medical medical_review" href="/d/html/6699.html" rel="external">"Medical thoracoscopy (pleuroscopy): Diagnostic and therapeutic applications", section on 'Diagnostic evaluation of an exudative pleural effusion of unknown etiology'</a>.)</p><p></p><p class="bulletIndent1">Thoracoscopic pleural biopsy, in the form of video-assisted thoracoscopic surgery or pleuroscopy (also called medical thoracoscopy), has a diagnostic yield for malignant pleural effusions that is superior to percutaneous pleural biopsy [<a href="#rid35">35,36</a>]. However, a negative thoracoscopic biopsy does not fully exclude malignant pleural disease, especially mesothelioma and rarely, may need to be repeated to increase the chances of yielding a positive result. These data are discussed separately. (See  <a class="medical medical_review" href="/d/html/89115.html" rel="external">"Procedures for tissue biopsy in patients with suspected non-small cell lung cancer", section on 'Suspected pleural metastases'</a>.)</p><p></p><p class="headingAnchor" id="H3564662754"><span class="h2">Biopsy results</span><span class="headingEndMark"> — </span>Some biopsy findings provide a clear diagnosis. For example, microorganisms found on tissue specimens or tissue culture may confirm parapneumonic effusion while malignant cells confirm malignant pleural effusion.</p><p>Some pathologic findings found on pleural biopsy may be nondiagnostic but support the clinical suspicion (eg, noncaseating granulomas [sarcoidosis, rheumatoid pleuritis], pleuritis [connective tissue disease]). As such, they may not warrant additional testing or follow-up.</p><p>It should be emphasized that "chronic fibrinous pleuritis" and "nonspecific pleuritis" are descriptive pathologic terms and should not be considered a clinical diagnosis. We consider these patients as having an undiagnosed pleural effusion and manage them as such. Some are eventually diagnosed with malignancy during follow-up [<a href="#rid37">37,38</a>]. (See <a class="local">'Follow-up and outcomes'</a> below.)</p><p class="headingAnchor" id="H14"><span class="h2">Follow-up and outcomes</span><span class="headingEndMark"> — </span>In many cases, an etiology is not identified, even after extensive investigations, including pleural biopsy. In this population, we observe both the patient and the effusion closely, paying attention to identifying "treatable" causes of a pleural effusion (eg, tuberculosis, lymphoma) [<a href="#rid39">39</a>]. We typically start with clinical evaluation and chest radiography in two to three weeks, sooner if the patient has new or progressive symptoms. We then follow the patient thereafter until the effusion improves, resolves, stabilizes, or worsens. The British Thoracic Society suggests follow-up for up to two years in patients with a undiagnosed pleural effusion [<a href="#rid8">8</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Improvement or resolution</strong> – If the pleural effusion improves without specific treatment, we continue to observe until complete resolution.</p><p></p><p class="bulletIndent1">Overall, patients with idiopathic pleural effusions generally have favorable outcomes [<a href="#rid40">40,41</a>]. Many cases resolve or improve spontaneously, but the time required for resolution varies depending upon the underlying etiology while others persist and remain without a clear etiology [<a href="#rid40">40-45</a>]. In a retrospective study of 83 patients with undiagnosed "idiopathic" effusions, 57 percent resolved and 24 percent improved, and 19 percent persisted during follow-up [<a href="#rid41">41</a>]. Biochemical pleural fluid analysis did not predict these outcomes.</p><p></p><p class="bulletIndent1">In such cases, a viral etiology is often presumed [<a href="#rid46">46</a>] but rarely proven. For example, in patients with coronavirus disease 2019 (COVID-19) who had a pleural effusion, most spontaneously improved and none demonstrated any evidence of the virus in pleural fluid [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features", section on 'Imaging findings'</a>.)</p><p></p><p class="bulletIndent1">Uncomplicated parapneumonic effusions and effusions from pulmonary embolism, tuberculous pleurisy, and postcardiac injury syndrome may persist for several weeks. Benign asbestos pleural effusion, rheumatoid pleurisy, and radiation pleuritis often persist for months to years. Other effusions that may persist for years include those caused by lymphatic abnormalities (eg, yellow-nail syndrome and pulmonary lymphangiectasia) and those associated with nonexpandable lung [<a href="#rid48">48,49</a>]. (See  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a> and  <a class="medical medical_review" href="/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults"</a> and  <a class="medical medical_review" href="/d/html/8012.html" rel="external">"Tuberculous pleural effusion"</a> and  <a class="medical medical_review" href="/d/html/6703.html" rel="external">"Evaluation and management of pleural effusions following cardiac surgery"</a> and  <a class="medical medical_review" href="/d/html/6697.html" rel="external">"Diagnosis and management of pleural causes of nonexpandable lung"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progression or stable effusion</strong> – Among patients without a clear etiology, only a small proportion of patients develop a persistent or worsening pleural effusion (eg, &lt;20 percent) during follow-up [<a href="#rid41">41</a>]. If patients show signs of symptomatic or radiologic progression, we typically repeat the evaluation most often beginning with repeat CT and pleural fluid analysis, followed by biopsy, if necessary. For patients with a stable pleural effusion during follow-up, we continue observation.</p><p></p><p class="bulletIndent1">In a small proportion of patients, the cause of the pleural effusion may become obvious during follow-up, although the diagnoses are variable (eg, malignancy, tuberculosis). In one series of 53 patients who had nonspecific pleuritis after pleural fluid analyses and thoracoscopic biopsies, almost half received a diagnosis in the subsequent two years, typically parapneumonic effusion and congestive heart failure; only a small proportion (4 percent) were diagnosed with malignancy [<a href="#rid44">44</a>]. In another series of 52 patients with nonspecific pleurisy on thoracoscopic biopsy, a malignant diagnosis was revealed in 15 percent after a median follow-up of 35.5 months while 44 percent had benign disease [<a href="#rid45">45</a>].</p><p></p><p class="headingAnchor" id="H1827005110"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112226.html" rel="external">"Society guideline links: Pleural effusion"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial approach</strong> – Pleural effusions can develop as a result of over 50 different pleuropulmonary or systemic disorders of both benign and malignant etiologies. (See <a class="local">'Initial approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We take a detailed history, perform a thorough examination, and obtain necessary imaging targeted at the most common etiologies, which are cancer, heart failure, and parapneumonic infections. We also pay attention to identifying other potential etiologies, including: comorbid conditions; drugs; occupational exposures; risk factors for pulmonary embolism, tuberculosis (TB), and malignancy; recent procedures; and extrapleural sources for a pleural effusion. This assessment is critical for narrowing the differential and deciding what pleural fluid biomarkers to obtain for initial pleural fluid analysis. (See <a class="local">'History and examination'</a> above and <a class="local">'Advanced thoracic imaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most patients who have a newly detected pleural effusion of unclear etiology should undergo diagnostic thoracentesis (eg, 50 mL). Exceptions include congestive heart failure with typical features, insufficient pleural effusion volumes, and the presence of contraindications. For patients with a moderate to large symptomatic pleural effusion, we suggest withdrawing a larger volume for symptom relief (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Thoracentesis indications and contraindications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We obtain routine pleural fluid biomarkers (eg, cell counts and cell differential, total protein, lactate dehydrogenase, glucose, cholesterol) as well as select condition-specific pleural fluid biomarkers (eg, pleural fluid culture and Gram stain when infection is suspected, cytology if malignancy is suspected, lipid analysis if chylothorax is suspected). The selection and interpretation of pleural fluid biomarkers are discussed separately. (See <a class="local">'Initial pleural fluid analysis'</a> above and  <a class="medical medical_review" href="/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preliminary diagnosis</strong> – In most patients, clinical findings together with chest imaging and pleural fluid analysis (usually one, sometimes two thoracenteses) are generally sufficient to make a preliminary diagnosis. The diagnosis is typically easily made in patients who clearly have a transudative  (<a class="graphic graphic_table graphicRef73530" href="/d/graphic/73530.html" rel="external">table 4</a>) or an exudative  (<a class="graphic graphic_table graphicRef54055" href="/d/graphic/54055.html" rel="external">table 5</a>) pleural effusion with positive condition-specific biomarkers in the right clinical setting. Common diagnoses that are made using this approach are listed in the tables  (<a class="graphic graphic_table graphicRef50027" href="/d/graphic/50027.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef139766" href="/d/graphic/139766.html" rel="external">table 7</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional evaluation for undiagnosed pleural effusion</strong> – The cause of a pleural effusion is not evident in more than a quarter of patients after initial pleural fluid analysis. In such patients, subspecialty consultation with a pulmonologist is reasonable to assess the need for all or any the following options:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Retake the history and examination and reanalyze the pleural fluid</strong> – We typically rereview the history and examination, consider the possibility of uncommon or rare etiologies, and reanalyze the pleural fluid. Reanalyzing the pleural fluid may involve recalculation of the parameters that distinguish transudative and exudative effusions, particularly in patients with borderline or discrepant results. It may also involve adding condition-specific biomarkers, if needed (eg, amylase for suspected pancreatic effusion), and/or reanalyzing a fresh sample of pleural fluid (eg, repeat cytology for suspected malignant pleural effusion). (See <a class="local">'Retake the history and examination'</a> above and  <a class="medical medical_review" href="/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion", section on 'Condition-specific biomarkers'</a> and  <a class="medical medical_review" href="/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion", section on 'Classification as exudative or transudative'</a> and <a class="local">'Reanalyze pleural fluid'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Additional imaging</strong> – If indicated, we perform additional imaging targeted at confirming suspected etiologies or excluding serious etiologies (eg, positron emission tomography or CT pulmonary angiography). (See <a class="local">'Consider additional imaging'</a> above and  <a class="medical medical_review" href="/d/html/6688.html" rel="external">"Imaging of pleural effusions in adults"</a> and  <a class="medical medical_review" href="/d/html/4399.html" rel="external">"Imaging of pleural plaques, thickening, and tumors"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pleural biopsy</strong> – If the etiology still remains undetermined at this point, we typically perform a pleural biopsy with the goal of confirming or excluding serious conditions that can be diagnosed pathologically, such as cancer or TB. (See <a class="local">'Pleural biopsy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Choosing among the available options is dependent upon factors including the suspected etiology, local expertise, and type of pleural involvement (eg, focal or diffuse, mass or ill-defined thickening). (See <a class="local">'Choosing biopsy mode'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Some biopsy findings are diagnostic (eg, cancer cells that indicate malignant pleural effusion) while others are nonspecific findings that may support the clinical suspicion (eg, noncaseating granulomas [sarcoidosis, rheumatoid pleuritis], pleuritis [connective tissue disease]). (See <a class="local">'Biopsy results'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Follow up</strong> – For patients in whom an etiology is not identified despite extensive investigation, we observe the patient and the effusion closely for up to two years. We typically start with clinical evaluation and chest radiography in approximately two to three weeks, sooner if patients have new or progressive symptoms. (See <a class="local">'Follow-up and outcomes'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the pleural effusion improves without specific treatment, we continue to observe until complete resolution. Approximately three-quarters of patients resolve or improve and are often presumed to have a viral pleuritis or other benign condition.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If patients show signs of progression, we typically repeat the evaluation, most often beginning with repeat chest CT and pleural fluid analysis, followed by biopsy, if necessary. Almost half of these patients receive a diagnosis during follow-up, although the diagnoses are variable (eg, malignancy, tuberculosis).</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Porcel JM, Esquerda A, Vives M, Bielsa S. Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. Arch Bronconeumol 2014; 50:161.</a></li><li><a class="nounderline abstract_t">Huggins JT, Sahn SA. Drug-induced pleural disease. Clin Chest Med 2004; 25:141.</a></li><li><a class="nounderline abstract_t">Abramov Y, Elchalal U, Schenker JG. Pulmonary manifestations of severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril 1999; 71:645.</a></li><li><a class="nounderline abstract_t">Cadranel J, Canellas A, Matton L, et al. Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. Eur Respir Rev 2019; 28.</a></li><li><a class="nounderline abstract_t">Robinson BW, Musk AW. Benign asbestos pleural effusion: diagnosis and course. Thorax 1981; 36:896.</a></li><li><a class="nounderline abstract_t">Yilmaz U, Polat G, Sahin N, et al. CT in differential diagnosis of benign and malignant pleural disease. Monaldi Arch Chest Dis 2005; 63:17.</a></li><li><a class="nounderline abstract_t">Kozmic SE, Wayne DB, Feinglass J, et al. Factors Associated with Inpatient Thoracentesis Procedure Quality at University Hospitals. Jt Comm J Qual Patient Saf 2016; 42:34.</a></li><li><a class="nounderline abstract_t">Hooper C, Lee YC, Maskell N, BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 Suppl 2:ii4.</a></li><li><a class="nounderline abstract_t">Bintcliffe OJ, Hooper CE, Rider IJ, et al. Unilateral Pleural Effusions with More Than One Apparent Etiology. A Prospective Observational Study. Ann Am Thorac Soc 2016; 13:1050.</a></li><li><a class="nounderline abstract_t">Daniels CE, Ryu JH. Improving the safety of thoracentesis. Curr Opin Pulm Med 2011; 17:232.</a></li><li><a class="nounderline abstract_t">Hibbert RM, Atwell TD, Lekah A, et al. Safety of ultrasound-guided thoracentesis in patients with abnormal preprocedural coagulation parameters. Chest 2013; 144:456.</a></li><li><a class="nounderline abstract_t">Puchalski J. Thoracentesis and the risks for bleeding: a new era. Curr Opin Pulm Med 2014; 20:377.</a></li><li><a class="nounderline abstract_t">Cantey EP, Walter JM, Corbridge T, Barsuk JH. Complications of thoracentesis: incidence, risk factors, and strategies for prevention. Curr Opin Pulm Med 2016; 22:378.</a></li><li><a class="nounderline abstract_t">McVay PA, Toy PT. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991; 31:164.</a></li><li><a class="nounderline abstract_t">Mahmood K, Shofer SL, Moser BK, et al. Hemorrhagic complications of thoracentesis and small-bore chest tube placement in patients taking clopidogrel. Ann Am Thorac Soc 2014; 11:73.</a></li><li><a class="nounderline abstract_t">Patel MD, Joshi SD. Abnormal preprocedural international normalized ratio and platelet counts are not associated with increased bleeding complications after ultrasound-guided thoracentesis. AJR Am J Roentgenol 2011; 197:W164.</a></li><li><a class="nounderline abstract_t">Ault MJ, Rosen BT, Scher J, et al. Thoracentesis outcomes: a 12-year experience. Thorax 2015; 70:127.</a></li><li><a class="nounderline abstract_t">Mercaldi CJ, Lanes SF. Ultrasound guidance decreases complications and improves the cost of care among patients undergoing thoracentesis and paracentesis. Chest 2013; 143:532.</a></li><li><a class="nounderline abstract_t">Mayo PH, Goltz HR, Tafreshi M, Doelken P. Safety of ultrasound-guided thoracentesis in patients receiving mechanical ventilation. Chest 2004; 125:1059.</a></li><li><a class="nounderline abstract_t">Gervais DA, Petersein A, Lee MJ, et al. US-guided thoracentesis: requirement for postprocedure chest radiography in patients who receive mechanical ventilation versus patients who breathe spontaneously. Radiology 1997; 204:503.</a></li><li><a class="nounderline abstract_t">Goligher EC, Leis JA, Fowler RA, et al. Utility and safety of draining pleural effusions in mechanically ventilated patients: a systematic review and meta-analysis. Crit Care 2011; 15:R46.</a></li><li><a class="nounderline abstract_t">Collins TR, Sahn SA. Thoracocentesis. Clinical value, complications, technical problems, and patient experience. Chest 1987; 91:817.</a></li><li><a class="nounderline abstract_t">Creaney J, Lee YC. Diagnoses (Not Diagnosis) of Pleural Effusion. Time to Consider Concurrent Etiologies. Ann Am Thorac Soc 2016; 13:1003.</a></li><li><a class="nounderline abstract_t">Wrightson JM, Stanton AE, Maskell NA, et al. Pseudochylothorax without pleural thickening: time to reconsider pathogenesis? Chest 2009; 136:1144.</a></li><li><a class="nounderline abstract_t">Yap E, Anderson G, Donald J, et al. Pleural effusion in patients with pulmonary embolism. Respirology 2008; 13:832.</a></li><li><a class="nounderline abstract_t">Porcel JM, Madroñero AB, Pardina M, et al. Analysis of pleural effusions in acute pulmonary embolism: radiological and pleural fluid data from 230 patients. Respirology 2007; 12:234.</a></li><li><a class="nounderline abstract_t">Orki A, Akin O, Tasci AE, et al. The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases. Thorac Cardiovasc Surg 2009; 57:217.</a></li><li><a class="nounderline abstract_t">Qureshi NR, Rahman NM, Gleeson FV. Thoracic ultrasound in the diagnosis of malignant pleural effusion. Thorax 2009; 64:139.</a></li><li><a class="nounderline abstract_t">Raptis CA, McWilliams SR, Ratkowski KL, et al. Mediastinal and Pleural MR Imaging: Practical Approach for Daily Practice. Radiographics 2018; 38:37.</a></li><li><a class="nounderline abstract_t">Ryan CJ, Rodgers RF, Unni KK, Hepper NG. The outcome of patients with pleural effusion of indeterminate cause at thoracotomy. Mayo Clin Proc 1981; 56:145.</a></li><li><a class="nounderline abstract_t">Koegelenberg CF, Bolliger CT, Theron J, et al. Direct comparison of the diagnostic yield of ultrasound-assisted Abrams and Tru-Cut needle biopsies for pleural tuberculosis. Thorax 2010; 65:857.</a></li><li><a class="nounderline abstract_t">Maskell NA, Gleeson FV, Davies RJ. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. Lancet 2003; 361:1326.</a></li><li><a class="nounderline abstract_t">Metintas M, Yildirim H, Kaya T, et al. CT Scan-Guided Abrams' Needle Pleural Biopsy versus Ultrasound-Assisted Cutting Needle Pleural Biopsy for Diagnosis in Patients with Pleural Effusion: A Randomized, Controlled Trial. Respiration 2016; 91:156.</a></li><li><a class="nounderline abstract_t">Zhou X, Jiang P, Huan X, et al. Ultrasound-Guided versus Thoracoscopic Pleural Biopsy for Diagnosing Tuberculous Pleurisy Following Inconclusive Thoracentesis: A Randomized, Controlled Trial. Med Sci Monit 2018; 24:7238.</a></li><li><a class="nounderline abstract_t">Metintas M, Ak G, Dundar E, et al. Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial. Chest 2010; 137:1362.</a></li><li><a class="nounderline abstract_t">Wan YY, Zhai CC, Lin XS, et al. Safety and complications of medical thoracoscopy in the management of pleural diseases. BMC Pulm Med 2019; 19:125.</a></li><li><a class="nounderline abstract_t">Davies HE, Nicholson JE, Rahman NM, et al. Outcome of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies. Eur J Cardiothorac Surg 2010; 38:472.</a></li><li><a class="nounderline abstract_t">Wrightson JM, Davies HE. Outcome of patients with nonspecific pleuritis at thoracoscopy. Curr Opin Pulm Med 2011; 17:242.</a></li><li class="breakAll">Maskell, NA. Undiagnosed pleural effusions. In: Textbook of Pleural Diseases, 2nd ed, Light, RW, Lee, YCG (Eds), Arnold Press, London 2008. p.491.</li><li><a class="nounderline abstract_t">Venekamp LN, Velkeniers B, Noppen M. Does 'idiopathic pleuritis' exist? Natural history of non-specific pleuritis diagnosed after thoracoscopy. Respiration 2005; 72:74.</a></li><li><a class="nounderline abstract_t">Alemán C, Sanchez L, Alegre J, et al. Differentiating between malignant and idiopathic pleural effusions: the value of diagnostic procedures. QJM 2007; 100:351.</a></li><li><a class="nounderline abstract_t">Poe RH, Israel RH, Utell MJ, et al. Sensitivity, specificity, and predictive values of closed pleural biopsy. Arch Intern Med 1984; 144:325.</a></li><li><a class="nounderline abstract_t">Leslie WK, Kinasewitz GT. Clinical characteristics of the patient with nonspecific pleuritis. Chest 1988; 94:603.</a></li><li><a class="nounderline abstract_t">Gunluoglu G, Olcmen A, Gunluoglu MZ, et al. Long-term Outcome of Patients With Undiagnosed Pleural Effusion. Arch Bronconeumol 2015; 51:632.</a></li><li><a class="nounderline abstract_t">Yang Y, Wu YB, Wang Z, et al. Long-term outcome of patients with nonspecific pleurisy at medical thoracoscopy. Respir Med 2017; 124:1.</a></li><li><a class="nounderline abstract_t">Nestor J, Huggins T, Kummerfeldt C, et al. Viral diseases affecting the pleura. J Clin Virol 2013; 58:367.</a></li><li><a class="nounderline abstract_t">Cantley RL, Hrycaj S, Konopka K, et al. Cytologic findings in effusions from patients with SARS-CoV-2 infection. J Am Soc Cytopathol 2021; 10:261.</a></li><li><a class="nounderline abstract_t">Huggins JT, Sahn SA, Heidecker J, et al. Characteristics of trapped lung: pleural fluid analysis, manometry, and air-contrast chest CT. Chest 2007; 131:206.</a></li><li><a class="nounderline abstract_t">Nordkild P, Kromann-Andersen H, Struve-Christensen E. Yellow nail syndrome--the triad of yellow nails, lymphedema and pleural effusions. A review of the literature and a case report. Acta Med Scand 1986; 219:221.</a></li></ol></div><div id="topicVersionRevision">Topic 6707 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24360987" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15062606" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Drug-induced pleural disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10202873" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pulmonary manifestations of severe ovarian hyperstimulation syndrome: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31597674" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7336367" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Benign asbestos pleural effusion: diagnosis and course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16035560" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : CT in differential diagnosis of benign and malignant pleural disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26685932" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Factors Associated with Inpatient Thoracentesis Procedure Quality at University Hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20696692" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27064965" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Unilateral Pleural Effusions with More Than One Apparent Etiology. A Prospective Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21346571" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Improving the safety of thoracentesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23493971" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Safety of ultrasound-guided thoracentesis in patients with abnormal preprocedural coagulation parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24852328" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Thoracentesis and the risks for bleeding: a new era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27093476" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Complications of thoracentesis: incidence, risk factors, and strategies for prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1996485" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24102190" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hemorrhagic complications of thoracentesis and small-bore chest tube placement in patients taking clopidogrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21700980" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Abnormal preprocedural international normalized ratio and platelet counts are not associated with increased bleeding complications after ultrasound-guided thoracentesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25378543" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Thoracentesis outcomes: a 12-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23381318" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Ultrasound guidance decreases complications and improves the cost of care among patients undergoing thoracentesis and paracentesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15006969" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Safety of ultrasound-guided thoracentesis in patients receiving mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9240544" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : US-guided thoracentesis: requirement for postprocedure chest radiography in patients who receive mechanical ventilation versus patients who breathe spontaneously.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21288334" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Utility and safety of draining pleural effusions in mechanically ventilated patients: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3581930" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Thoracocentesis. Clinical value, complications, technical problems, and patient experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27388398" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Diagnoses (Not Diagnosis) of Pleural Effusion. Time to Consider Concurrent Etiologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19809057" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pseudochylothorax without pleural thickening: time to reconsider pathogenesis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18657058" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pleural effusion in patients with pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17298456" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Analysis of pleural effusions in acute pulmonary embolism: radiological and pleural fluid data from 230 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19670115" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18852159" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Thoracic ultrasound in the diagnosis of malignant pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29320326" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mediastinal and Pleural MR Imaging: Practical Approach for Daily Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7206790" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The outcome of patients with pleural effusion of indeterminate cause at thoracotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19996342" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Direct comparison of the diagnostic yield of ultrasound-assisted Abrams and Tru-Cut needle biopsies for pleural tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12711467" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26779911" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : CT Scan-Guided Abrams' Needle Pleural Biopsy versus Ultrasound-Assisted Cutting Needle Pleural Biopsy for Diagnosis in Patients with Pleural Effusion: A Randomized, Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30303950" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ultrasound-Guided versus Thoracoscopic Pleural Biopsy for Diagnosing Tuberculous Pleurisy Following Inconclusive Thoracentesis: A Randomized, Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20154079" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31291926" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Safety and complications of medical thoracoscopy in the management of pleural diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20219385" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Outcome of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21519267" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Outcome of patients with nonspecific pleuritis at thoracoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21519267" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Outcome of patients with nonspecific pleuritis at thoracoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15753638" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Does 'idiopathic pleuritis' exist? Natural history of non-specific pleuritis diagnosed after thoracoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17525131" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Differentiating between malignant and idiopathic pleural effusions: the value of diagnostic procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6696570" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Sensitivity, specificity, and predictive values of closed pleural biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3409743" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical characteristics of the patient with nonspecific pleuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26216715" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long-term Outcome of Patients With Undiagnosed Pleural Effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28284315" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Long-term outcome of patients with nonspecific pleurisy at medical thoracoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23916378" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Viral diseases affecting the pleura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33753013" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cytologic findings in effusions from patients with SARS-CoV-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17218577" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Characteristics of trapped lung: pleural fluid analysis, manometry, and air-contrast chest CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3962735" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Yellow nail syndrome--the triad of yellow nails, lymphedema and pleural effusions. A review of the literature and a case report.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
